

## REVIEW ARTICLE OPEN



# Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN)

Georg Maschmeyer<sup>1</sup>✉, Lars Bullinger<sup>2</sup>, Carolina Garcia-Vidal<sup>3</sup>, Raoul Herbrecht<sup>4</sup>, Johan Maertens<sup>5</sup>, Pierantonio Menna<sup>6</sup>, Livio Pagano<sup>7</sup>, Anne Thiebaut-Bertrand<sup>8</sup> and Thierry Calandra<sup>9</sup>

© The Author(s) 2022

The 9th web-based European Conference on Infections in Leukemia (ECIL-9), held September 16-17, 2021, reviewed the risk of infections and febrile neutropenia associated with more recently approved immunotherapeutic agents and molecular targeted drugs for the treatment of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Novel antibody based treatment approaches (inotuzumab ozogamicin, gemtuzumab ozogamicin, flotetuzumab), isocitrate dehydrogenases inhibitors (ivosidenib, enasidenib, olutasidenib), FLT3 kinase inhibitors (gilteritinib, midostaurin, quizartinib), a hedgehog inhibitor (glasdegib) as well as a BCL2 inhibitor (venetoclax) were reviewed with respect to their mode of action, their immunosuppressive potential, their current approval and the infectious complications and febrile neutropenia reported from clinical studies. Evidence-based recommendations for prevention and management of infectious complications and specific alerts regarding the potential for drug-drug interactions were developed and discussed in a plenary session with the panel of experts until consensus was reached. The set of recommendations was posted on the ECIL website for a month for comments from members of EBMT, EORTC, ICHS and ELN before final approval by the panelists. While a majority of these agents are not associated with a significantly increased risk when used as monotherapy, caution is required with combination therapy such as venetoclax plus hypomethylating agents, gemtuzumab ozogamicin plus cytotoxic drugs or midostaurin added to conventional AML chemotherapy.

*Leukemia*; <https://doi.org/10.1038/s41375-022-01556-7>

## INTRODUCTION

For several decades, intensive combination chemotherapy, with or without hematopoietic cell transplantation, has been the backbone for the treatment of acute leukemia in younger and fit patients, whereas less toxic regimens (e.g., use of hypomethylating agents) have been used in older and unfit patients. However, over the past 10–15 years, tremendous progress has been made in deciphering the molecular pathogenesis and phenotypic diversity

of acute leukemia. Several intracellular signaling pathways that are critical to the genesis of this disease have been identified. This new knowledge has also revealed various immunological and molecular therapeutic targets, paving the way for precision medicine approaches, both for acute myeloid leukemia and acute lymphoblastic leukemia. Recently, several small-molecule inhibitors and immunotherapies have been successfully introduced, either as single agents or in combination with standard-of-care

<sup>1</sup>Certified Cancer Center, Klinikum Ernst von Bergmann, Charlottenstrasse 72, D-14467 Potsdam, Germany. <sup>2</sup>Department of Hematology, Oncology and Tumor Immunology, Campus Virchow, Charité – Universitätsmedizin Berlin, German Cancer Consortium (DKTK), Partner Site Berlin, Berlin, Germany. <sup>3</sup>Infectious Diseases Department, Hospital Clinic-IDIBAPS, Villarroel 170, BCN 08036 Barcelona, Spain. <sup>4</sup>Department of Hematology, Institut de Cancérologie Strasbourg, Europe (ICANS) and Université de Strasbourg, Inserm, UMR-S1113/IRFAC, Strasbourg, France. <sup>5</sup>Department of Microbiology, Immunology, and Transplantation, KULeuven, Leuven and Department of Hematology, UZLEUVEN, Leuven, Belgium. <sup>6</sup>Department of Sciences and Technologies for Humans and the Environment, University Campus Bio-Medico of Rome, University Hospital Foundation Campus Bio-Medico of Rome, Rome, Italy. <sup>7</sup>Hematology Division, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli – IRCCS and Università Cattolica del Sacro Cuore, Rome, Italy. <sup>8</sup>Department of Hematology, Grenoble University Hospital, Grenoble, France. <sup>9</sup>Infectious Diseases Service, Department of Medicine, Lausanne University Hospital, University of Lausanne, CH-1011 Lausanne, Switzerland. ✉email: gm-k@gmx.de

Received: 3 March 2022 Revised: 17 March 2022 Accepted: 22 March 2022

Published online: 02 April 2022

**Table 1.** Grading system used for strength of recommendation and quality of evidence (after [1]).

Strength of recommendation	
Grade	Definition
A	ECIL strongly supports a recommendation for use
B	ECIL moderately supports a recommendation for use
C	ECIL marginally supports a recommendation for use
D	ECIL supports a recommendation against use
Quality of evidence	
Level	Definition
I	Evidence from at least 1 properly designed randomized, controlled trial (orientated on the primary endpoint of the trial)
II*	Evidence from at least 1 well-designed clinical trial (including secondary endpoints), without randomization; from cohort or case-controlled analytic studies (preferably from > 1 center); from multiple time series; or from dramatic results of uncontrolled experiments
III	Evidence from opinions of respected authorities, based on clinical experience, descriptive case studies, or reports of expert committees
Added index for source of level ii evidence	
*Index	Source
r	Meta-analysis or systematic review of RCT
t	Transferred evidence, that is, results from different patient cohorts, or similar immune-status situation
h	Comparator group: historical control
u	Uncontrolled trials
a	Published abstract presented at an international symposium or meeting

therapies. The introduction or the addition of these novel therapies may potentially alter the landscape of infectious complications that are normally seen in these immunocompromised leukemia patients. In addition, the potential for hazardous drug-drug interactions when combining these novel agents with currently used anti-infective drugs, either prophylactically or therapeutically, underscores the need for more individualized and personalized treatment. This position paper updates our knowledge of infections associated with these agents and provides recommendations for a rational clinical management of prevention and treatment of infections in leukemia patients treated with immunotherapeutic and molecular targeted antineoplastic agents, given with or without standard therapy.

## METHODS

In early 2021, the Executive Committee of ECIL nominated a group of experts in clinical hematology and oncology, infectious diseases and clinical pharmacology. The panel of experts established a list of drugs and immune-based therapies to be reviewed. Subgroups of experts reviewed the literature on specific agents and agreed on timelines. A literature search (Medline) up to 1 September 2021, using the MeSH terms "(Substance name)" AND (1) "mode of action", (2) "immunosuppression" OR "immune system" OR "immune defense" (3) "toxicity" OR "adverse" OR "infection" OR "fever" was set up and the state of drug approval in 2021 (globally and regionally) determined. Subgroup members selected relevant publications for data analysis and extracted all relevant data from clinical reports to prepare summaries on the mode of action, the impact on immune defense and the state of approval. They prepared sets of recommendations on diagnostic procedures in

case of fever and/or infection, management strategies (including the need for antimicrobial prophylaxis) and handling of the drug. Panelists compiled a complete slide set discussed in several consecutive online group meetings and electronic communication until two weeks before the online ECIL-9 plenary meeting. Panelists received the consented slide set by email prior to the plenary. On the day of the meeting (September 17, 2021), the slides were presented by each subgroup of experts and interactively discussed during a 3-h session. Subgroup members reviewed in closed sessions the comments made by panel members and revised recommendations accordingly. The revised set of recommendations was presented to the ECIL-9 plenary in a late afternoon session on the same day and discussed until reaching consensus. The approved slide set was published on the ECIL website (<https://ecil-leukaemia.com/en/resources/resources-ecil>) for comments over a month (November 2021). Members of the expert subgroups approved the final set of recommendations. For grading of the strength of recommendation and the level of evidence, the European Society of Clinical Microbiology and Infectious Disease (ESCMID) grading system [1] was used (Table 1).

## RESULTS AND RECOMMENDATIONS

For a summary of drug characteristics, reported infectious complications and ECIL clinical practice recommendations see Table 2.

### Inotuzumab ozogamicin

Inotuzumab ozogamicin (InO) is used as targeted therapy for adults with relapsed and/or refractory CD22-positive B-cell precursor ALL. It binds with high affinity to CD22, a cell-surface antigen expressed by >90% of B-cell blasts in nearly all patients with B-cell ALL. InO is an Ig4 antibody-drug conjugate composed of a humanized anti-CD22 monoclonal antibody conjugated to a derivative of the cytotoxic agent calicheamicin. The cytotoxic agent is released intracellularly and induces DNA strand cleavage, with the subsequent cell death mediated through calicheamicin-induced apoptosis and not by CD22 signaling. It was approved in 2017 for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. The impact of CD22 inhibition on immunity is unclear. CD22 regulates multiple B cell functions, but the role of CD22 in protection against pathogens is not well established.

In a phase 3 randomized clinical trial (RCT) in patients with relapsed or refractory ALL, comparing 109 InO treated patients with 109 patients receiving standard therapy, febrile neutropenia was noted in 11 vs 18% of patients, pneumonia in 4% vs 1%, sepsis 2% vs 5% and septic shock 1% vs 1% of patients respectively [2].

In a phase 2 RCT, InO in combination with low-intensity chemotherapy (mini-hyper-CVD) vs InO monotherapy in 59 vs 84 patients with relapsed or refractory B-precursor ALL, infections were noted in 73% vs 17% of patients [3].

In a phase 2 RCT, mini-hyper-CVD in combination with InO plus or minus blinatumomab maintenance was given as first salvage treatment to patients with relapsed/refractory B-precursor ALL; infections occurred in 67% of patients undergoing InO plus mini-hyper-CVD therapy, one patient had sepsis [4].

In a phase 3 RCT, InO vs standard therapy was administered to patients with relapsed/refractory B-precursor ALL; febrile neutropenia was noted in 11.6% vs 18.9%, sepsis in 2.4% vs 7%, septic shock in 1.8% vs 2.1%, pneumonia in 6.1% vs 0% and fungal infection in 0 vs 2.1% of patients [5].

Prolongation of QT interval has been observed in patients receiving InO. Therefore, the concomitant use of InO with medicinal products known to prolong the QT interval or induce Torsades de pointes must be carefully evaluated. The QT interval must be monitored in case of combination of these medicines [6].

**Table 2.** Summary of drug characteristics, reported infectious complications and ECIL clinical practice recommendations for targeted drugs and biotherapies in acute leukemia.

<b>Class of agents</b>	<b>Agent</b>	<b>Impact on immune system</b>	<b>Infectious events</b>	<b>ECIL recommendations</b>
Anti-CD22 antibody-drug conjugate	Inotuzumab ozogamicin	No documented mechanism of immunosuppression	When combined with chemotherapy: febrile neutropenia, sepsis, pneumonia	<ul style="list-style-type: none"> <li>• No specific antimicrobial prophylaxis (A-Ilr)</li> <li>• No specific recommendation with the use of this drug in case of infection or fever</li> <li>• Special attention when combining this drug with other agents prolonging QT interval, such as levofloxacin or posaconazole (A-Ilr)</li> </ul>
Anti-CD33 antibody-drug conjugate	Gemtuzumab ozogamicin	No specific impact on immune defense except neutropenia	When given in combination with chemotherapy: febrile neutropenia, pneumonia, sepsis, fungal infection)	<p>Recommended diagnostic procedures:</p> <ul style="list-style-type: none"> <li>• Standard of care in AML and neutropenic fever and/or infections (A-Ilr)</li> </ul> <p>Treatment recommendations:</p> <ul style="list-style-type: none"> <li>• Standard of care in neutropenic fever and/or infections (A-Ilr)</li> </ul> <p>Recommendations for prophylaxis:</p> <ul style="list-style-type: none"> <li>• Standard of care in AML, when given in combination (A-Ilr) or high-dose GO for relapse (A-Ilr)</li> <li>• No systemic antimicrobial prophylaxis when given as monotherapy (A-Ilr)</li> </ul> <p>Recommendations on how to handle the drug in case of infection or fever:</p> <ul style="list-style-type: none"> <li>• Most infections occur subsequent to GO application, therefore no recommendation General recommendation</li> <li>• Careful monitoring of hepatotoxicity (A-I)</li> </ul>
CD123 x CD3 bispecific dual-affinity retargeting antibody (DART)	Flotetuzumab	No documented mechanism of immunosuppression	No specific risks of infection in patients on flotetuzumab monotherapy	<p>Recommended diagnostic procedures:</p> <ul style="list-style-type: none"> <li>• Standard of care in AML and neutropenic fever and/or infections (A-Ilr)</li> </ul> <p>Treatment recommendations:</p> <ul style="list-style-type: none"> <li>• Standard of care in neutropenic fever and/or infections (A-Ilr)</li> </ul> <p>Recommendations for prophylaxis:</p> <ul style="list-style-type: none"> <li>• No specific recommendation due to lack of data when given as monotherapy</li> </ul> <p>Recommendations on how to handle the drug in case of infection:</p> <ul style="list-style-type: none"> <li>• No specific recommendation due to lack of data when given as monotherapy</li> </ul>
Isocitrate dehydrogenase (IDH)-1 and -2 inhibitors	Enasidenib, ivosidenib, olutasidenib	No documented mechanism of immunosuppression	Reports on severe differentiation syndrome which may mimic an infection (fever, acute respiratory distress, pulmonary infiltrates, pleural or pericardial effusion, hyperleukocytosis, renal impairment, multiorgan failure)	<p>Recommended diagnostic procedures:</p> <ul style="list-style-type: none"> <li>• Standard of care in AML and neutropenic fever and/or infections (A-Ilr)</li> </ul> <p>Treatment recommendations:</p> <ul style="list-style-type: none"> <li>• Standard of care in neutropenic fever and/or infections (A-Ilr)</li> </ul> <p>Recommendations for prophylaxis:</p> <ul style="list-style-type: none"> <li>• No systemic antimicrobial prophylaxis when given as monotherapy (A-Ilr)</li> </ul> <p>Recommendations on how to handle the drug in case of infection:</p> <ul style="list-style-type: none"> <li>• No specific recommendations</li> </ul>
FLT3-Tyrosine Kinase Inhibitor, also active against receptor tyrosine kinases KIT and AXL	Gilteritinib	No documented mechanism of immunosuppression	Infections in relapsed and/or refractory AML patients on gilteritinib: febrile neutropenia, sepsis pneumonia	<p>Recommended diagnostic procedures:</p> <ul style="list-style-type: none"> <li>• Standard of care in AML and neutropenic fever and/or infections (A-Ilr)</li> </ul> <p>Treatment recommendations:</p> <ul style="list-style-type: none"> <li>• Standard of care in neutropenic fever and/or infections (A-Ilr)</li> </ul> <p>Recommendations for prophylaxis:</p> <ul style="list-style-type: none"> <li>• No systemic antimicrobial prophylaxis when given as monotherapy (A-Ilr)</li> </ul>

Table 2. continued

Class of agents	Agent	Impact on immune system	Infectious events	ECIL recommendations
Multi-tyrosine kinase inhibitor of Fms-Like Receptor Tyrosine Kinase 3 (FLT3), KIT, platelet derived growth factor receptor (PDGFR), vascular endothelial growth factor receptor 2 (VEGFR2) and members of the serine/threonine kinases of the protein kinase C (PKC) family	Midostaurin	No specific impact on immune defense except neutropenia	Febrile neutropenia, respiratory tract infections, sepsis, herpes simplex virus infections	<p>Recommendations on how to handle the drug in case of infection:</p> <ul style="list-style-type: none"> <li>No specific recommendations</li> </ul> <p>Recommendations on how to handle the drug in case of concomitant administration of strong CYP3A4 inhibitors (e.g., itraconazole, posaconazole, voriconazole):</p> <ul style="list-style-type: none"> <li>Close monitoring for QT interval prolongation (A-I)</li> </ul> <p>Recommendations on how to handle the drug if current medication includes a strong CYP3A4 inducer:</p> <ul style="list-style-type: none"> <li>Avoid combination</li> </ul> <p>Recommended diagnostic procedures in case of fever:</p> <ul style="list-style-type: none"> <li>Standard of care for fever during cytarabine/anthracycline chemotherapy plus midostaurin therapy (A-IIr)</li> </ul> <p>Treatment recommendations:</p> <ul style="list-style-type: none"> <li>Use of empirical antibiotic therapy during cytarabine/anthracycline chemotherapy plus midostaurin therapy in neutropenic fever and/or infections (A-IIr)</li> </ul> <p>Recommendations for antimicrobial prophylaxis:</p> <ul style="list-style-type: none"> <li>Standard of care when midostaurin is given in combination with cytarabine/anthracycline chemotherapy (A-IIr)</li> <li>No need for antibacterial or antifungal prophylaxis when given as monotherapy (A-IIr)</li> </ul> <p>Recommendations for concurrent use of CYP3A4 inducers or inhibitors:</p> <ul style="list-style-type: none"> <li>Warning for drug-drug interaction (see package insert): strong CYP3A4 inhibitors (clarithromycin, antifungal triazoles, cobicistat, antiviral protease, integrase, NS5A or polymerase inhibitors used for HIV and/or hepatitis C treatment) may increase exposure to midostaurin or its metabolites. Consider alternative therapies that do not strongly inhibit CYP3A4 or monitor for increased risk of adverse reactions.</li> <li>Avoid concomitant use of strong CYP3A4 inducers such as rifampin.</li> </ul>
Selective Fms-Like Receptor Tyrosine Kinase 3 (FLT3) tyrosine kinase inhibitor	Quizartinib	No specific impact on immune defense apart from neutropenia.	When used in combination with chemotherapy: febrile neutropenia and bacterial infections (sepsis, urinary tract infection, respiratory tract infection)	<p>Recommended diagnostic procedures:</p> <ul style="list-style-type: none"> <li>Standard of care in AML and neutropenic fever and/or infections (A-IIr)</li> </ul> <p>Treatment recommendations:</p> <ul style="list-style-type: none"> <li>Use of empirical antibiotic approach in neutropenic fever and/or infections (A-IIr)</li> </ul> <p>Recommendations for antibiotic prophylaxis:</p> <ul style="list-style-type: none"> <li>Standard of care in AML, when given in combination (A-IIr)</li> </ul> <p>Recommendations for combination with CYP3A4 inducing or inhibiting agents:</p> <ul style="list-style-type: none"> <li>See recommendations for gilteritinib</li> </ul>
Hedgehog pathway inhibitor	Glasdegib			

Table 2. continued

Class of agents	Agent	Impact on immune system	Infectious events	ECIL recommendations
B Cell Lymphoma (BCL)-2 protein inhibitor	Venetoclax	No specific impact on immune defense apart from neutropenia	When given in combination with chemotherapy: febrile neutropenia, pneumonia, sepsis	<p><b>ECIL recommendations</b></p> <ul style="list-style-type: none"> <li>Recommended diagnostic procedures:</li> <li>Standard of care in AML and neutropenic fever and/or infections (A-IIr)</li> <li>Treatment recommendations:</li> <li>Standard of care in neutropenic fever and/or infections (A-IIr)</li> <li>Recommendations for prophylaxis:</li> <li>Standard of care in AML, when given in combination with chemotherapy (A-IIr)</li> <li>Recommendations on how to handle the drug in case of infection:</li> <li>No specific recommendations</li> <li>Recommendations on combination with CYP3A4 inhibiting or inducing agents:</li> <li>Critical reconsideration of concomitant erythromycin, clarithromycin, ciprofloxacin, itraconazole, posaconazole, ketoconazole or voriconazole</li> <li>Avoidance of combination with strong CYP3A4 inducers (see above)</li> </ul>
		Neutropenia	When given in combination with 5-azacitidine: febrile neutropenia, pneumonia, sepsis	<p>Recommended diagnostic procedures:</p> <ul style="list-style-type: none"> <li>Standard of care in AML and neutropenic fever and/or infections (A-IIr)</li> <li>Treatment recommendations:</li> <li>Standard of care in neutropenic fever and/or infections (A-IIr)</li> <li>Recommendations for prophylaxis:</li> <li>Standard of care as for AML treatment with intensive chemotherapy (A-IIr)</li> <li>Further recommendations for prophylaxis: <ul style="list-style-type: none"> <li>Consider antibacterial and antifungal prophylaxis when hypomethylating agents are combined with venetoclax (A-IIr)</li> </ul> </li> <li>Recommendations on how to handle the drug in case of infection:</li> <li>Consider dose interruptions to allow for hematologic recovery in patients with a response (based on early bone marrow assessment, most importantly after the completion of cycle 1) (A-I)</li> <li>Promote appropriate interruptions in venetoclax between treatment cycles to augment hematologic recovery (A-I)</li> <li>In patients with good response but severe neutropenia, consider venetoclax dose reduction in subsequent courses (A-IIr)</li> <li>If dose reduction is ineffective or not advised, consider prophylactic granulocyte colony-stimulating factor during remission for subsequent courses (C-IIr)</li> <li>Recommendations for concurrent use of venetoclax with antimicrobial agents: <ul style="list-style-type: none"> <li>Ensure proper venetoclax dose adjustments when venetoclax is combined with macrolides (A-I)</li> <li>If posaconazole is given in combination with venetoclax, reduce venetoclax dose by 75% (A-I)</li> </ul> </li> </ul>

Risk of infection associated with inotuzumab ozogamicin:

- Inotuzumab ozogamicin monotherapy does not increase the risk of infection.

Recommendations:

- No specific antimicrobial prophylaxis is needed (A-IIr).
- No specific recommendation with the use of this drug in case of infection or fever.
- Special attention when combining this drug with other agents prolonging QT interval, such as levofloxacin or posaconazole (A-IIr).

### Gemtuzumab ozogamicin

Gemtuzumab ozogamicin (GO) is a recombinant humanized anti-CD33 monoclonal antibody conjugated to a derivative of calicheamicin. This conjugated antibody is rapidly internalized and causes subsequent apoptosis. CD33 is expressed on monocytes, granulocytes, mast cells and myeloid progenitors. Apart from profound neutropenia, no specific impact on immune defense has been described for GO. It is approved for the treatment of AML expressing CD33 in patients. It is used in combination with daunorubicin and cytarabine, but may also be applied as a monotherapy.

In a randomized phase 3 trial in elderly, newly diagnosed AML patients ( $n = 237$ ) unfit for induction chemotherapy, GO ( $6 \text{ mg/m}^2$  day 1 plus  $3 \text{ mg/m}^2$  day 8) was compared with best supportive care (BSC) [7]. Infections (with no further details reported) were documented in 44.1% vs 42.1%, and febrile neutropenia in 35.1% and 34.2% of patients, respectively. There was no difference in grade  $\geq 3$  infections or FN.

In another randomized phase 3 trial in 472 newly diagnosed elderly AML patients [8], induction chemotherapy using mitoxantrone, cytarabine and etoposide with vs without preceding two GO doses of  $6 \text{ mg/m}^2$  on days 1 and 15 was administered. Infections (without further details reported) were documented in 55% of patients in both arms, and FN in 35% vs 31% of patients with vs without GO pretreatment.

GO in a dosage of  $6 \text{ mg/m}^2$  every 4 weeks was compared with no further treatment for consolidation in 232 AML patients  $\geq 60$  years of age in complete remission after two conventional chemotherapy induction cycles with daunorubicin plus cytarabine followed by high-dose cytarabine [9]. Infections grade 2–4 (no further details reported) were observed in 43% of patients undergoing up to three GO consolidation cycles, including sepsis in 10%. A fatal infection did not occur.

Standard remission induction chemotherapy (cytarabine plus daunorubicin, "7 + 3") with or without GO ( $3 \text{ mg/m}^2$  on days 1, 4 and 7) was given to 268 AML patients in a randomized phase 3 trial [10]. Infections were documented in 77.6% of patients with no difference between the two groups. Breaking down the types of infections and FN, no significant differences between the two patient groups were reported in the supplement to this publication.

Another randomized phase 3 trial in 586 AML patients [11] compared similar two treatment modalities with GO given in a dosage of  $6 \text{ mg/m}^2$  on day 4 of induction. Fatal infections were noted in 5 of 292 (1.7%) patients with GO and 2 of 294 (0.7%) of patients without GO. No further details were reported.

Induction chemotherapy with idarubicin, cytarabine, etoposide and all-trans retinoic acid with or without GO ( $3 \text{ mg/m}^2$  day 1) was given to 549 patients with de novo, *nucleophosmin-1* (*NPM1*) mutated AML in a randomized phase 3 study [12]. All-grade infections emerged in 79% of 274 patients treated with additional GO vs 73% of 275 patients without GO. No further details were reported with respect to infections.

De novo AML patients ( $n = 46$ ) were treated in a single-arm trial with induction chemotherapy including fludarabine, cytarabine and idarubicin plus GO ( $3 \text{ mg/m}^2$  day 4), and the outcome was compared to a matched historical control group treated with the same induction chemotherapy without GO [13]. Infections were noted in 16 of 46 (34.8%) patients treated with GO and 25 of 47 (53.2%) patients treated with chemotherapy alone. Details on infectious complications were not reported.

Patients with first AML relapse ( $n = 277$ ) were treated with GO monotherapy in a dosage of  $9 \text{ mg/m}^2$  for two doses separated by two weeks in an open label phase 2 trial [14]. Grade 3 or 4 adverse events included sepsis (17%), fever (13%), pneumonia (8%) and FN (6%). Within 28 days after the last GO dose, 44 patients (16%) had died, 13 of them (4.7% of total) from infection.

In 48 patients with relapsed (first or higher relapse) or refractory AML salvage treatment with fludarabine, cytarabine, idarubicin and granulocyte colony-stimulating factor plus GO ( $9 \text{ mg/m}^2$  day 8) was given and outcomes compared with 23 matched control patients treated with the same salvage regimen without GO [15]. Documented fungal infections were noted in 2 of 23 (9%) patients without GO and 9 of 48 (19%) patients with GO, the difference being statistically non-significant. The fungal infections were predominantly attributed to *Candida* species.

Severe hepatic adverse events may emerge in patients undergoing GO therapy. In vitro, N-acetyl gamma calicheamicin dimethyl hydrazide is primarily metabolized via nonenzymatic reduction. Therefore, coadministration of GO with inhibitors or inducers of cytochrome P450 or uridine diphosphate glucuronosyltransferase (UGT) drug metabolizing enzymes are unlikely to alter exposure to N-acetyl gamma calicheamicin dimethyl hydrazide.

Risk of infection associated with gemtuzumab ozogamicin:

- No specific risk of infection is associated with GO monotherapy.
- In large comparative trials on chemotherapy  $\pm$  GO, no significant increase of neutropenic fever/infections was specifically attributable to GO.
- Types of infectious events reported were fever of unknown origin (FUO), pneumonia, sepsis and fungal infection, with no potentially GO-related infections.

Recommended diagnostic procedures:

- Standard of care in AML and neutropenic fever and/or infections (A-IIr).

Treatment recommendations:

- Standard of care in neutropenic fever and/or infections (A-IIr).

Recommendations for prophylaxis:

- Standard of care in AML, when given in combination (A-IIr) or high-dose GO for relapse (A-IIr).

- No systemic antimicrobial prophylaxis when given as monotherapy (A-IIr).

Recommendations on how to handle the drug in case of infection:

- Most infections occur subsequent to GO application, therefore no recommendation.

General recommendation:

- Careful monitoring of hepatotoxicity (A-I).

### Flotetuzumab

Flotetuzumab is an investigational CD123 x CD3 bispecific dual-affinity retargeting antibody (DART) molecule. CD123 is the interleukin-3 receptor alpha chain expressed both at the level of leukemic stem cells and more differentiated leukemic blasts. Flotetuzumab application point at redirection of T lymphocytes to attack CD123-expressing cells. Flotetuzumab in a clinically applied dosage does not result in significant and prolonged suppression of normal hematopoiesis [16]. In non-human primates, no neutropenia or thrombocytopenia was observed [17].

While flotetuzumab has no FDA or EMA approval yet (as of January 2022), it is available in Japan and accessible in Europe through an expanded access program (NCT04678466). FDA has granted orphan drug designation to flotetuzumab for the treatment of AML. The only published clinical data available originate from a study in refractory AML [16]. In this phase 1/2 study, 88 patients with refractory AML or intermediate/high-risk MDS were treated with several flotetuzumab dosages and schedules, some with addition of ruxolitinib and the anti-IL6 antibody tocilizumab. Patients with active infections were excluded. Flotetuzumab-related infections were not observed. FN was reported for 13.6% of 44 patients presented at the 2020 annual meeting of the American Society of Hematology (ASH) [18].

Risk of infection associated with flotetuzumab:

- No specific risks of infection in patients on flotetuzumab monotherapy.

Recommended diagnostic procedures:

- Standard of care in AML and neutropenic fever and/or infections (A-IIr).

Treatment recommendations:

- Standard of care in neutropenic fever and/or infections (A-IIr).

Recommendations for prophylaxis:

- No specific recommendation due to lack of data when given as monotherapy.

Recommendations on how to handle the drug in case of infection:

- No specific recommendation due to lack of data when given as monotherapy.

### IDH-1 and IDH-2 inhibitors (enasidenib, ivosidenib, olutasidenib)

Isocitrate dehydrogenases (IDH)-1 mutations are found in 6–10% of the patients with AML, IDH-2 mutations in 9–13%. Mutations in IDH-1 and -2 are almost always mutually exclusive and are present in a variety of other malignancies such as myelodysplastic syndrome, angioimmunoblastic T-cell lymphomas, gliomas, cholangiocarcinomas, chondrosarcomas and medulloblastomas [19]. Enasidenib (against IDH-2), ivosidenib and olutasidenib (both against IDH-1) are orally available small molecules inhibiting mutant IDH. For olutasidenib, no clinical study results are available as yet. Enasidenib was approved for relapsed and refractory IDH-2 positive AML treatment by the FDA in 2017; ivosidenib was FDA approved in 2019 for newly-diagnosed AML with a susceptible IDH-1 mutation in patients who are at least 75 years old or who have comorbidities that preclude the use of intensive induction chemotherapy. The EMA approval for these compounds was withdrawn by their specific companies in 2020.

No specific immunosuppressive effect of enasidenib or ivosidenib has been reported as yet. Ivosidenib in contrast to enasidenib is

predominantly metabolized by CYP3A4, resulting in an increased exposure to ivosidenib when given in combination with strong inhibitors of CYP3A4 including triazole antifungals. The ivosidenib package insert indicates a warning for an increased risk of QTc interval prolongation in patients given this drug in combination with moderate or strong CYP3A4 inhibitors.

IDH inhibitors can cause a severe differentiation syndrome which may mimic an infection. The potential symptoms include fever, acute respiratory distress, pulmonary infiltrates, pleural or pericardial effusion, hyperleukocytosis or renal impairment up to multiorgan failure.

In a phase 1 study in 258 patients with relapsed or refractory AML patients treated with ivosidenib monotherapy [20], febrile neutropenia was noted in 25.2% and pneumonia (all grades) in 14.7%. No association with the study drug was observed. In 179 patients treated with the standard dose of ivosidenib 500 mg daily, febrile neutropenia occurred in 28.5% of patients. In a subgroup of 34 patients ineligible for standard chemotherapy due to age and/or comorbidities, who were treated with 500 mg ivosidenib daily, febrile neutropenia and pneumonia were documented in 3 patients each [21].

In a dose-finding phase 1 study, ivosidenib in combination with azacitidine was administered to 23 AML patients unfit for standard chemotherapy [22]. Febrile neutropenia was noted in 43.5% and lung infection (no further details reported) in 17.4% of patients.

The IDH-2 inhibitor enasidenib as monotherapy was studied in 345 patients IDH-2 mutated, relapsed or refractory AML [23]. No febrile neutropenia nor any type of infection was reported among treatment-related adverse events occurring in more than 5% of patients.

In another report on enasidenib monotherapy in 17 patients with IDH-2 mutant MDS [24], pneumonia was noted in 5 patients (29%) without further details described, and 3 patients (18%) has a differentiation syndrome.

In an open-label, single-arm trial, enasidenib was given in 39 “unfit” patients with newly diagnosed, IDH-2 mutant AML [25]. No treatment-related grade 3–4 adverse event was observed, however, pneumonia was reported for 7 (18%) patients, while a treatment relation was denied.

Ivosidenib (500 mg/day) or enasidenib (100 mg/day) were combined with intensive remission induction and consolidation chemotherapy in 151 patients with newly diagnosed, IDH-1 or -2 mutated AML in a phase 1 study [26]. Fever was reported in 26.7% of ivosidenib and 33.3% of enasidenib combination therapy recipients during induction and in 22.9% and 28.3% of patients during consolidation. Notably, clostridia infections were documented in 13.3% and 18.3% of patients during induction and in 5.7% and 10.9% of patients during consolidation therapy. While this has been a multicenter study, no discussion on a specific center effect or any other explanation for this unusual finding is provided. Ivosidenib/enasidenib monotherapy arms were not included, so that it remains unclear, if febrile events or clostridial infections were attributable to the IDH inhibitor.

Risk of infection associated with enasidenib or ivosidenib:

- No specific risks of infection in patients on enasidenib or ivosidenib monotherapy.

Recommended diagnostic procedures:

- Standard of care in AML and neutropenic fever and/or infections (A-IIr).

In combination with more intensive antileukemic treatment, clostridia infections were reported from a single center.

Treatment recommendations:

- Standard of care in neutropenic fever and/or infections (A-IIr).

Recommendations for prophylaxis:

- No systemic antimicrobial prophylaxis when given as monotherapy (A-IIr).

Recommendations on how to handle the drug in case of infection:

- No specific recommendations

**Gilteritinib.** Gilteritinib is a highly selective oral FLT3 (Fms-Like Receptor Tyrosine Kinase 3) inhibitor with activity against both FLT3 mutation subtypes (Internal Tandem Duplication and Tyrosine Kinase Domain). It has a weak activity against KIT, suggesting a lower risk of myelosuppression when used for leukemia treatment. Gilteritinib also inhibits the tyrosine kinase AXL, resulting not only in a reduction of proliferation of AML cells, but also in immune suppression associated with AXL activity [27]. Gilteritinib is approved for the treatment of relapsed and refractory FLT3-mutated AML by FDA and EMA.

In an open-label phase 1/2 study, gilteritinib in a dose of 20–450 mg/day was given to 252 patients with relapsed/refractory AML irrespective of FLT3 mutation status [28]. Febrile neutropenia was documented in 40% of patients, with sepsis in 14%, pneumonia in 4%, and clostridial colitis in 2% of patients.

When randomized in a dosage of 120 mg/day versus salvage chemotherapy in a phase 3 study in 247 patients with FLT3-mutated, relapsed or refractory AML [29], febrile neutropenia was noted in 46.7% of patients given gilteritinib vs 36.7% in patients undergoing salvage chemotherapy (difference not significant), while treatment-related pneumonia was reported for 14.4% of patients treated with gilteritinib vs 17.3% of patients undergoing salvage chemotherapy.

Gilteritinib co-administered with strong CYP3A4 inhibitors (such as itraconazole, posaconazole or voriconazole) or inducers (such as rifampicin, rifamycin, rifapentine or rifaximin) may cause an increase or decrease of gilteritinib levels [30]. When one of the above-mentioned triazole antifungal is given concomitantly with gilteritinib, a dose reduction does not appear to be required, however, a close monitoring of potential QT interval prolongation is recommended. Whenever possible, the concomitant administration of gilteritinib and a strong CYP3A4 inducer should be avoided. Prescribing information should be noted ([https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2019/211349s001lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211349s001lbl.pdf)).

Risk of infection associated with gilteritinib:

- While no specific impact on immune defense has been reported, infections reported in relapsed and/or refractory AML patients on gilteritinib are sepsis, febrile neutropenia and pneumonia.

Recommended diagnostic procedures:

- Standard of care in AML and neutropenic fever and/or infections (A-IIr).

Treatment recommendations:

- Standard of care in neutropenic fever and/or infections (A-IIr).

Recommendations for prophylaxis:

- No systemic antimicrobial prophylaxis when given as monotherapy (A-IIr).

Recommendations on how to handle the drug in case of infection:

- No specific recommendations.

Recommendations on how to handle the drug in case of concomitant administration of strong CYP3A4 inhibitors (e.g., itraconazole, posaconazole, voriconazole):

- Close monitoring for QT interval prolongation (A-I).

Recommendations on how to handle the drug if current medication includes a strong CYP3A4 inducer:

- Avoid combination.

**Midostaurin.** Midostaurin inhibits multiple tyrosine kinase receptors, including FLT3 and KIT kinases. It induces cell cycle arrest and apoptosis via the inhibition of FLT3 receptor signaling in AML cells with mutant FLT3 internal tandem duplications (ITD), tyrosine kinase domain (TKD) mutated receptors or overexpression of wild-type FLT3 receptors. In addition, midostaurin inhibits many other tyrosine kinase receptors such as platelet derived growth factor receptor (PDGFR), vascular endothelial growth factor receptor 2 (VEGFR2) or members of the serine/threonine kinases of the protein kinase C (PKC) family. Midostaurin in combination with chemotherapeutic agents (cytarabine, doxorubicin, idarubicin or daunorubicin) results in a synergistic inhibition of the growth of AML cell lines expressing FLT3-ITD. Apart from neutropenia, midostaurin has no impact on immune defense.

Midostaurin is approved for the treatment of adults with newly diagnosed FLT3-mutated AML. Used upfront in combination with chemotherapy, midostaurin is continued as monotherapy for maintenance therapy after favorable response. Midostaurin is also approved for the treatment of aggressive systemic mastocytosis and mast cell leukemia. The prescription information for midostaurin contains a warning against combination of this drug with strong CYP3A4 inhibitors and more explicitly with strong CYP3A4 inducers.

Eleven phase 1 to 4 studies published between 2010 and 2020 were included in this review. Study populations consisted of patients with either newly diagnosed or relapsing/refractory AML. Midostaurin was used as monotherapy in two studies and in combination with standard chemotherapeutic regimens in nine. The median number of patients included was 69 (range: 11–717). The proportion of patients with febrile neutropenia ranged from 20% to 82% (median: 35%). Only four studies provided information on the frequency of infections [31–34] and four reported on the frequency of sepsis [34–37]. Pneumonia was the most frequent type of infection. It was reported in seven studies at a frequency ranging from 2% to 23% (median: 9%) [31, 35–40]. Other types of infections included upper respiratory tract infections (including sinusitis), cellulitis and bacteremias. The frequency of sepsis ranged from 4% to 18%. Bacterial infections tend to be frequent when midostaurin is used in combination with other cytotoxic drugs and much less so when used in monotherapy. Very few studies reported on the occurrence of fungal and viral infections which occurred at low frequencies (<10%) [36, 41]. This included one episode of pulmonary mycosis and two episodes of unspecified mycoses requiring antifungal therapy with an azole [34, 36] and seven episodes of herpes simplex infections [41].

Risk of infection associated with midostaurin:

- No specific impact on immune defense apart from neutropenia.

Recommended diagnostic procedures in case of fever:

- Standard of care for fever during cytarabine/anthracycline chemotherapy plus midostaurin therapy (A-IIr).

Treatment recommendations:



- Use of empirical antibiotic therapy during cytarabine/anthracycline chemotherapy plus midostaurin therapy in neutropenic fever and/or infections (A-IIr).

#### Recommendations for antimicrobial prophylaxis:

- Standard of care when midostaurin is given in combination with cytarabine/anthracycline chemotherapy (A-IIr).
- No need for antibacterial or antifungal prophylaxis when given as monotherapy (A-IIr).

#### Recommendations for concurrent use of CYP3A4 inducers or inhibitors:

- Warning for drug-drug interaction (see package insert): strong CYP3A4 inhibitors (clarithromycin, antifungal triazoles, cobicistat, antiviral protease, integrase, NS5A or polymerase inhibitors used for HIV and/or hepatitis C treatment) may increase exposure to midostaurin or its metabolites. Consider alternative therapies that do not strongly inhibit CYP3A4 or monitor for increased risk of adverse reactions.
- Avoid concomitant use of strong CYP3A4 inducers such as rifampin.

**Quizartinib.** Quizartinib is a potent and selective FLT3 tyrosine kinase inhibitor with significant activity in FLT3-ITD-mutant AML. The quality and duration of achievable response thus far seen with this agent as monotherapy is suboptimal. Quizartinib in combination with chemotherapy might result in improved outcome. Although the drug was granted FDA breakthrough designation in 2018, quizartinib has not been approved by FDA nor by EMA. To date, only the Ministry of Health, Labor and Welfare (MHLW) of Japan has approved quizartinib for the treatment of adult patients with relapsed/refractory FLT3-ITD-positive AML. When used to treat AML, the most common side effects with quizartinib were infections: 19% sepsis/septic shock, 12% pneumonia; grade 3 QT prolongation was seen in 3–4% of patients [42].

In a phase 1 study of quizartinib monotherapy administered daily (orally at escalating doses of 12–450 mg/day) to 76 patients with relapsed or refractory AML irrespective of FLT3-ITD status, only two cases of fever (3%) and one lung infection (1%, not otherwise specified) was noted [43]. Similar results were described in two other phase 1 studies. When quizartinib (40–60 mg/day) was given as maintenance therapy in 13 subjects with AML in remission following allogeneic cell transplantation, the most common grade 3/4 adverse events were hematologic (including 23% neutropenia and 15% lymphopenia) with only one patient (8%) developing ‘pneumonia’ [44]. When combined with ‘standard of care’ chemotherapy in 19 newly diagnosed AML patients, 47% of patients developed febrile neutropenia (all grade 3); the authors did not report specific data on infections. Both studies concluded that attention should be given to the co-administration with QT prolonging drugs [45]. In a large, open-label, multicenter phase 2 study, a total of 333 patients with relapsed/refractory AML received quizartinib (135 mg/day for men; 90 mg/day for women) monotherapy. Febrile neutropenia grade 3 and 4 developed in 37% and 4% of patients, respectively. Thirty-one patients (9%) had grade 3 pneumonia; 4% had grade 4 or 5 pneumonia. Different grades of sepsis were noted in 25 patients (8%), ‘lung infection’ in 11 patients (3.3%), bacteremia in 10 patients (3%), cellulitis in 9 patients, fungal pneumonia in 9 patients, urinary tract infection (all grade 3) in 8 patients, and septic shock in 7 patients, respectively. Seven individuals (2.1%) developed *Clostridium difficile* colitis [46]. Additional phase 1 and 2 studies did not reveal any specific infectious risk related to quizartinib monotherapy in relapsed/refractory AML patients: febrile neutropenia and fever of unknown origin occurs in 21–43% of cases, pneumonia in 12–21% and

sepsis in 4–11% [47, 48]. In the open-label phase 3 QuANTUM-R trial, 245 patients with relapsed/refractory FLT3-ITD AML received quizartinib 60 mg/day and 122 patients received chemotherapy. The most common non-hematological grade 3–5 adverse events were sepsis or septic shock (46 patients [19%] for quizartinib vs 18 [19%] for chemotherapy) and pneumonia (29 [12%] vs eight [9%]). The most frequent treatment-related serious adverse events were febrile neutropenia (18 patients [7%]), sepsis or septic shock (11 [5%]), and QT prolongation (5 [2%]) in the quizartinib group, and febrile neutropenia (5 [5%]), sepsis or septic shock (4 [4%]), pneumonia (2 [2%]) in the chemotherapy group. Of note, *Clostridium difficile* infection was seen in 11 quizartinib-treated patients vs none in the chemotherapy group. Seven patients in the quizartinib group developed fungal pneumonia (3%) versus five in the chemotherapy group (5%) [49].

Co-administration of quizartinib with drugs that prolong the QT/QTc interval and moderate or strong CYP3A inducers was prohibited in the QuANTUM-R trial. Avoidance of strong CYP3A inhibitors was recommended but not prohibited; however, if they were used, quizartinib dose adjustments were required. Weak or moderate CYP3A inhibitors, such as fluconazole, were allowed without dose reduction.

#### Risk of infection associated with quizartinib:

- No specific impact on immune defense apart from neutropenia. Febrile neutropenia/FUO and bacterial infections are frequent, mainly sepsis, urinary tract infection or upper respiratory infection. Fungal or viral infections appear to be very rare.

#### Recommended diagnostic procedures:

- Standard of care in AML and neutropenic fever and/or infections (A-IIr).

#### Treatment recommendations:

- Use of empirical antibiotic approach in neutropenic fever and/or infections (A-IIr).

#### Recommendations for antibiotic prophylaxis:

- Standard of care in AML, when given in combination (A-IIr).

#### Recommendations for combination with CYP3A4 inducing or inhibiting agents:

- See recommendations for gilteritinib.

**Glasdegib.** Glasdegib is a small molecule inhibitor of sonic hedgehog, which is a protein overexpressed in many types of cancer. The Hedgehog pathway inhibitor glasdegib has been shown to chemosensitize leukemic stem cells (LSCs). It inhibits the sonic hedgehog receptor smoothed (SMO), a key mediator of Hedgehog pathway signaling in LSCs. Glasdegib works synergistically with low-dose cytarabine (LDAC). No specific impact on immune defense apart from neutropenia has been identified as yet.

Glasdegib is approved, in combination with LDAC, for the treatment of newly diagnosed de novo or secondary AML (excluding acute promyelocytic leukemia) in adult patients who are not candidates for standard induction chemotherapy. Glasdegib is given continuously as long as the patient is deriving clinical benefit.

In a phase 1 study on glasdegib monotherapy in 28 patients with relapsed or refractory AML, neutropenia was documented in one patient [50].

In a randomized phase 2 study, glasdegib in combination with low-dose cytarabine was compared with low-dose cytarabine alone for first-line treatment of AML or high-risk MDS patients unsuitable for

intensive chemotherapy [51]. Febrile neutropenia was reported for 35.7% vs 24.4% of patients, and pneumonia in 28.6% vs 24.4% of patients on combination vs low-dose cytarabine monotherapy.

When combined both with standard-dose cytarabine and daunorubicin ("7 + 3"), febrile neutropenia (mostly grade 3) was documented in 63.8% of patients, pyrexia in 49.3% and pneumonia and sepsis each in 10.1% of patients [52].

No specific risks of infection in patients on glasdegib monotherapy was reported. In clinical trials on glasdegib +LDAC, no signal of an increased risk of neutropenic fever/infections due to glasdegib was noted. Overall, febrile neutropenia, pneumonia and sepsis were reported in patients on combination glasdegib and intensive chemotherapy, with no potentially glasdegib-related infections.

Glasdegib is metabolized by CYP3A4/5, thus it is not recommended to use other drugs which inhibit CYP3A (such as erythromycin, clarithromycin, ciprofloxacin, posaconazole, voriconazole). A combination with strong CYP3A4 inducers such as rifampicin (see above) should be avoided [53].

Risk of infection associated with glasdegib:

- No specific impact on immune defense apart from neutropenia.

Recommended diagnostic procedures:

- Standard of care in AML and neutropenic fever and/or infections (A-IIr).

Treatment recommendations:

- Standard of care in neutropenic fever and/or infections (A-IIr).

Recommendations for prophylaxis:

- Standard of care in AML, when given in combination with chemotherapy (A-IIr).

Recommendations on how to handle the drug in case of infection:

- No specific recommendations.

Recommendations on combination with CYP3A4 inhibiting or inducing agents:

- Critical reconsideration of concomitant erythromycin, clarithromycin, ciprofloxacin, itraconazole, posaconazole, ketocazole or voriconazole.
- Avoidance of combination with strong CYP3A4 inducers (see above).

*Venetoclax. For a previous ECIL review on venetoclax used for lymphoma treatment, see [54].*

Venetoclax is a BH(BCL2-homology)-3 mimetic that blocks the anti-apoptotic B-cell lymphoma-2 (BCL-2) protein, resulting in programmed cell death of leukemia cells. Overexpression of BCL-2 is contributing to lymphoid and myeloid malignancies. No specific impact on immune defense apart from neutropenia has been identified so far.

Venetoclax is approved in combination with a hypomethylating agents such as azacitidine or decitabine for patients with newly diagnosed AML (excluding acute promyelocytic leukemia) who are ineligible for intensive chemotherapy.

In a single arm phase 2 study on high-dose venetoclax (800 mg/day) monotherapy in 32 patients with relapsed or refractory AML unfit for intensive chemotherapy [55], febrile neutropenia (all grade 3-4) was reported for 31% and pneumonia for 25% of patients.

In a pivotal randomized placebo-controlled phase 3 trial, venetoclax (target dose of 400 mg/day) in combination with azacitidine ( $n =$

283) was compared with azacitidine monotherapy ( $n = 144$ ) in newly diagnosed AML patients  $\geq 75$  years of age unfit for standard chemotherapy [56]. Febrile neutropenia was reported for 30% vs 10% of patients (log-rank test  $p < 0.001$ ), while pneumonia and sepsis were reported for 17% vs 22% and 6% vs 8% of patients on combination vs monotherapy, respectively. Infections of any grade occurred in 84% of the patients in the azacitidine-venetoclax group vs 67% of those in the azacitidine monotherapy group.

In a phase 1 study on venetoclax in a dose-escalation from 400 to 800 to 1200 mg/day, each in combination with azacitidine or decitabine, in elderly "unfit" patients with newly diagnosed AML [57], febrile neutropenia grade 3-4 was documented in up to 61% of patients, without an association with venetoclax dosage or one of the two hypomethylating agents. A low frequency of fungal infections (8% grade 3-4), despite exclusion of CYP3A inhibiting azole antifungals, which may be related to the prophylactic use of alternative antifungals such as echinocandins in 46% of patients.

A meta-analysis of eight reports on venetoclax in combination with hypomethylating agents in patients with AML or MDS [58] showed a febrile neutropenia rate of 47% (95% confidence interval 36–58%).

Venetoclax is metabolized by CYP3A4/5, specific attention must be paid when combined with other drugs which inhibit CYP3A (such as erythromycin, ciprofloxacin, triazoles). For the administration of posaconazole, as standard antifungal prophylaxis in AML patients undergoing myelosuppressive remission induction chemotherapy, an evidence-based recommendation for venetoclax dose reduction by 75% is available [59].

Risk of infection associated with venetoclax:

- No specific impact on immune defense apart from neutropenia.

Recommended diagnostic procedures:

- Standard of care in AML and neutropenic fever and/or infections (A-IIr).

Treatment recommendations:

- Standard of care in neutropenic fever and/or infections (A-IIr).

Recommendations for prophylaxis:

- Standard of care as for AML treatment with intensive chemotherapy (A-IIr).

Further recommendations for prophylaxis:

- Consider antibacterial and antifungal prophylaxis when hypomethylating agents are combined with venetoclax (A-IIr).

Recommendations on how to handle the drug in case of infection:

- Consider dose interruptions to allow for hematologic recovery in patients with a response (based on early bone marrow assessment, most importantly after the completion of cycle 1) (A-I).
- Promote appropriate interruptions in venetoclax between treatment cycles to augment hematologic recovery (A-I).
- In patients with good response but severe neutropenia, consider venetoclax dose reduction in subsequent courses (A-IIr).
- If dose reduction is ineffective or not advised, consider prophylactic granulocyte colony-stimulating factor during remission for subsequent courses (C-IIr).

Recommendations for concurrent use of venetoclax with antimicrobial agents:

- Ensure proper venetoclax dose adjustments when venetoclax is combined with antibacterial agents such as ciprofloxacin or macrolides (A-I).
- If posaconazole is given in combination with venetoclax, reduce venetoclax dose by 75% (A-I).

## REFERENCES

- Ullmann AJ, Cornely OA, Donnelly JP, Akova M, Arendrup MC, Arkan-Akdaglı S, et al. ESCMID guideline for the diagnosis and management of *Candida* diseases 2012: developing European guidelines in clinical microbiology and infectious diseases. *Clin Microbiol Infect.* 2012;18:1–8.
- Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. *N Engl J Med.* 2016;375:740–3.
- Jabbour E, Ravandi F, Kebriaei P, Huang X, Short NJ, Thomas D, et al. Salvage chemoinmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD for patients with relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: a phase 2 clinical trial. *JAMA Oncol.* 2018;4:230–4.
- Jabbour E, Sasaki K, Ravandi F, Huang X, Short NJ, Khouri M, et al. Chemoinmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage. *Cancer.* 2018;124:4044–55.
- Kantarjian HM, DeAngelo DJ, Stelljes M, Liedtke M, Stock W, Gökbuğut N, et al. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. *Cancer.* 2019;125:2474–87.
- Kebriaei P, Cutler C, de Lima M, Giralt S, Lee SJ, Marks D, et al. Management of important adverse events associated with inotuzumab ozogamicin: expert panel review. *Bone Marrow Transplant.* 2018;53:449–56.
- Amadori S, Suci S, Selleslag D, Aversa F, Gaidano G, Musso M, et al. Gemtuzumab ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy: results of the randomized phase III EORTC-GIMEMA AML-19 trial. *J Clin Oncol.* 2016;34:972–9.
- Amadori S, Suci S, Stasi R, Salih HR, Selleslag D, Muus P, et al. Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17). *J Clin Oncol.* 2013;31:4424–30.
- Löwenberg B, Beck J, Graux C, van Putten W, Schouten HC, Verdonck LF, et al. Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study. *Blood.* 2010;115:2586–91.
- Lambert J, Pautas C, Terré C, Raffoux E, Turlure P, Caillot D, et al. Gemtuzumab ozogamicin for de novo AML: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial. *Haematologica.* 2019;104:113–9.
- Petersdorf S, Kopecky KJ, Slovak M, Willman C, Nevill T, Brandwein J, et al. A phase 3 study of gemtuzumab ozogamicin during induction and post-consolidation therapy in younger patients with AML. *Blood.* 2013;121:4854–60.
- Schlenk RF, Paschka P, Krzykalla J, Weber D, Kapp-Schworer S, Gaidzik VI, et al. Gemtuzumab ozogamicin in NPM1-mutated AML: early results from the prospective randomized AMLSG 09-09 phase III study. *J Clin Oncol.* 2020;38:623–32.
- Clavio M, Vignolo L, Albarello A, Varaldo R, Pierri I, Catania G, et al. Adding low-dose gemtuzumab ozogamicin to fludarabine, Ara-C and idarubicin (MY-FLAI) may improve disease-free and overall survival in elderly patients with non-M3 AML: results of a prospective, pilot, multi-centre trial and comparison with a historical cohort of patients. *Br J Haematol.* 2007;138:186–95.
- Larson RA, Sievers EL, Stadtmauer EA, Löwenberg B, Estey EH, Dombret H, et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. *Cancer.* 2005;104:1442–52.
- Martin MG, Augustin KM, Uy GL, Welch JS, Hladnik L, Goyal S, et al. Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF. *Am J Hematol.* 2009;84:733–7.
- Uy GL, Aldoss I, Foster MC, Sayre PH, Wieduwilt MJ, Advani AS, et al. Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. *Blood.* 2021;137:751–62.
- Chichili GR, Huang L, Li H, Burke S, He L, Tang Q, et al. A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: preclinical activity and safety in nonhuman primates. *Sci Transl Med.* 2015;7:289ra82.
- Aldoss I, Uy GL, Vey N, Emadi A, Sayre PH, Walter RB, et al. Flotetuzumab as salvage therapy for primary induction failure and early relapse acute myeloid leukemia. *Blood.* 2020;Suppl 1:16–18.
- Waitkus MS, DiPlas BH, Yan H. Biological role and therapeutic potential of IDH mutations in cancer. *Cancer Cell.* 2018;34:186–95.
- DiNardo CD, Stein EM, de Botton S, Roboz GJ, Altman JK, Mims AS, et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. *N Engl J Med.* 2018;378:2386–98.
- Roboz GJ, DiNardo CD, Stein EM, de Botton S, Mims AS, Prince GT, et al. Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. *Blood.* 2020;135:463–71.
- DiNardo CD, Stein AS, Stein EM, Fathi AT, Frankfurt O, Schuh AC, et al. Mutant isocitrate dehydrogenase 1 inhibitor ivosidenib in combination with azacitidine for newly diagnosed acute myeloid leukemia. *J Clin Oncol.* 2021;39:57–65.
- Stein EM, DiNardo CD, Fathi AT, Pollyea DA, Stone RM, Altman JK, et al. Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. *Blood.* 2019;133:676–87.
- Stein EM, Fathi AT, DiNardo CD, Pollyea DA, Roboz GJ, Collins R, et al. Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial. *Lancet Haematol.* 2020;7:e309–e319.
- Pollyea DA, Tallman MS, de Botton S, Kantarjian HM, Collins R, Stein AS, et al. Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia. *Leukemia.* 2019;33:2575–84.
- Stein EM, DiNardo CD, Fathi AT, Mims AS, Pratz KW, Savona MR, et al. Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study. *Blood.* 2021;137:1792–803.
- Gay CM, Balaji K, Averett Byers L. Giving AXL the axe: targeting AXL in human malignancy. *Br J Cancer.* 2017;116:415–23.
- Perl AE, Altman JK, Cortes J, Smith C, Litzow M, Baer MR, et al. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. *Lancet Oncol.* 2017;18:1061–75.
- Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. *N Engl J Med.* 2019;381:1728–40.
- James AJ, Smith CC, Litzow M, Perl AE, Altman JK, Shepard D, et al. Pharmacokinetic profile of gilteritinib: a novel FLT-3 tyrosine kinase inhibitor. *Clin Pharmacokinet.* 2020;59:1273–90.
- Schlenk RF, Weber D, Fiedler W, Salih HR, Wulf G, Salwender H, et al. Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD. *Blood.* 2019;133:840–51.
- Stone RM, Fischer T, Paquette R, Schiller G, Schiffer CA, Ehninger G, et al. Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia. *Leukemia.* 2012;26:2061–8.
- Strati P, Kantarjian H, Ravandi F, Nazha A, Borthakur G, Daver N, et al. Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome. *Am J Hematol.* 2015;90:276–81.
- Tomlinson BK, Gallogly MM, Kane DM, Metheny L, Lazarus HM, William BM, et al. A phase II study of midostaurin and 5-azacytidine for untreated elderly and unfit patients with FLT3 wild-type acute myelogenous leukemia. *Clin Lymphoma Myeloma Leuk.* 2020;20:226–233.e1.
- Cooper BW, Kindwall-Keller TL, Craig MD, Creger RJ, Hamadani M, Tse WW, et al. A phase I study of midostaurin and azacitidine in relapsed and elderly AML patients. *Clin Lymphoma Myeloma Leuk.* 2015;15:428–432.e2.
- Ramsingh G, Westervelt P, McBride A, Stockerl-Goldstein K, Vij R, Fiala M, et al. Phase I study of cladribine, cytarabine, granulocyte colony stimulating factor (CLAG regimen) and midostaurin and all-trans retinoic acid in relapsed/refractory AML. *Int J Hematol.* 2014;99:272–8.
- Roboz GJ, Strickland SA, Litzow MR, Dalovisio A, Perl AE, Bonifacio G, et al. Updated safety of midostaurin plus chemotherapy in newly diagnosed FLT3 mutation-positive acute myeloid leukemia: the RADIUS-X expanded access program. *Leuk Lymphoma.* 2020;61:3146–53.
- Fischer T, Stone RM, Deangelo DJ, Galinsky I, Estey E, Lanza C, et al. Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. *J Clin Oncol.* 2010;28:4339–45.
- Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. *N Engl J Med.* 2017;377:454–64.
- Maziarz RT, Levis M, Patnaik MM, Scott BL, Mohan SR, Deol A, et al. Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia. *Bone Marrow Transplant.* 2021;56:1180–9.
- Berger T, Rozovski U, Moshe Y, Yaari S, Frisch A, Hellmann I, et al. Midostaurin in combination with intensive chemotherapy is safe and associated with improved

- remission rates and higher transplantation rates in first remission—a multi-center historical control study. *Ann Hematol.* 2019;98:2711–7.
42. Fletcher L, Joshi SK, Traer E. Profile of quizartinib for the treatment of adult patients with relapsed/refractory FLT3-ITD-positive acute myeloid leukemia: evidence to date. *Cancer Manag Res.* 2020;12:151–63.
  43. Cortes JE, Kantarjian H, Foran JM, Ghirdaladze D, Zodelava M, Borthakur G, et al. Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status. *J Clin Oncol.* 2013;31:3681–7.
  44. Sandmaier BM, Khaled S, Oran B, Gammon G, Trone D, Frankfort O. Results of a phase 1 study of quizartinib as maintenance therapy in patients with acute myeloid leukemia in remission following allogeneic hematopoietic stem cell transplant. *Am J Hematol.* 2018;93:222–31.
  45. Altman JK, Foran JM, Pratz KW, Trone D, Cortes JE, Tallman MS. Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia. *Am J Hematol.* 2018;93:213–21.
  46. Cortes J, Perl AE, Döhner H, Kantarjian H, Martinelli G, Kovacovics T, et al. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. *Lancet Oncol.* 2018;19:889–903.
  47. Takahashi T, Usuki K, Matsue K, Ohno H, Sakura T, Imanaka R, et al. Efficacy and safety of quizartinib in Japanese patients with FLT3-ITD positive relapsed or refractory acute myeloid leukemia in an open-label, phase 2 study. *Int J Hematol.* 2019;110:665–74.
  48. Usuki K, Handa H, Choi I, Yamauchi T, Iida H, Hata T, et al. Safety and pharmacokinetics of quizartinib in Japanese patients with relapsed or refractory acute myeloid leukemia in a phase 1 study. *Int J Hematol.* 2019;110:654–64.
  49. Cortes JE, Khaled S, Martinelli G, Perl AE, Ganguly S, Russell N, et al. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. *Lancet Oncol.* 2019;20:984–97.
  50. Martinelli G, Oehler VG, Papayannidis C, Courtney R, Shaik MN, Zhang X, et al. Treatment with PF-04449913, an oral smoothed antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study. *Lancet Haematol.* 2015;2:e339–346.
  51. Cortes JE, Heidel FH, Hellmann A, Fiedler W, Smith BD, Robak T, et al. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. *Leukemia.* 2019;33:379–89.
  52. Cortes JE, Douglas Smith B, Wang ES, Merchant A, Oehler VG, Arellano M, et al. Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: phase 2 study results. *Am J Hematol.* 2018;93:1301–10.
  53. Shaik MN, Hee B, Wei H, LaBadie RR. Evaluation of the effect of rifampin on the pharmacokinetics of the smoothed inhibitor glasdegib in healthy volunteers. *Br J Clin Pharmacol.* 2018;84:1346–53.
  54. Maschmeyer G, De Greef J, Mellinghoff SC, Nosari A, Thiebaut-Bertrand A, Bergeron A, et al. Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL). *Leukemia.* 2019;33:844–62.
  55. Konopleva M, Pollyea DA, Potluri J, Chyla B, Hogdal L, Busman T, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. *Cancer Discov.* 2016;6:1106–17.
  56. DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. *N Engl J Med.* 2020;383:617–29.
  57. DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, et al. Venetoclax combined with decitabine or azacitidine in treatment-naïve, elderly patients with acute myeloid leukemia. *Blood.* 2019;133:7–17.
  58. Liu B, Guo Y, Deng L, Qiao Y, Jian J. The efficacy and adverse events of venetoclax in combination with hypomethylating agents treatment for patients with acute myeloid leukemia and myelodysplastic syndrome: a systematic review and meta-analysis. *Hematology.* 2020;25:414–23.
  59. Agarwal SK, DiNardo CD, Potluri J, Dunbar M, Kantarjian HM, Humerickhouse RA, et al. Management of venetoclax-posaconazole interaction in acute myeloid leukemia patients: evaluation of dose adjustments. *Clin Ther.* 2017;39:359–67.

## ACKNOWLEDGEMENTS

The authors would like to thank the meeting participants of ECIL 9 virtual meeting on September 17, 2021: Robina Aerts (Leuven, Belgium), Michael Ankcorn (London, UK), Dina Averbuch (Jerusalem, Israel), Nicole Blijlevens (Nijmegen, The Netherlands), Paul Brennan-Benson (Surrey, UK), Lars Bullinger (Berlin, Germany), Alessandro Busca (Turin, Italy),

Thierry Calandra (Lausanne, Switzerland), Rafael de la Camara (Madrid, Spain), Simone Cesaro (Verona, Italy), Catherine Cordonnier (Paris, France), Carolina Garcia-Vidal (Barcelona, Spain), Andreas Groll (Münster, Germany), Raoul Herbrecht (Strasbourg, France), Giuseppe Indolfi (Florence, Italy), Gemma Johnson (Newcastle-upon-Tyne, UK), Frederic Lamoth (Lausanne, Switzerland), Per Ljungman (Stockholm, Sweden), Johan Maertens (Leuven, Belgium), Georg Maschmeyer (Potsdam, Germany), Sibylle Mellinghoff (Cologne, Germany), Pierantonio Menna (Rome, Italy), Sylvain Meylan (Lausanne, Switzerland), Malgorzata Mikulska (Genoa, Italy), Marcio Nucci (Rio de Janeiro, Brazil), Livio Pagano (Rome, Italy), Katia Perruccio (Perugia, Italy), Antonio Pagliuca (London, UK), Pedro Puerta (Barcelona, Spain), Christine Robin (Paris, France), Jan Styczynski (Bydgoszcz, Poland), Anne Thiebaut-Bertrand (Grenoble, France), Marie von Lilienfeld-Toal (Jena, Germany), Lewis White (Cardiff, UK).

## AUTHOR CONTRIBUTIONS

All co-authors prepared a set of summary slides on each of the substances addressed in the manuscript, presented the slides at the virtual ECIL-9 conference and revised the slide sets after the plenary discussion. GM prepared the manuscript, all co-authors revised the text and consented the final version.

## COMPETING INTERESTS

GM received honoraria for lectures from Gilead Sciences, Bristol-Myers Squibb, Merck-Serono, Amgen, AstraZeneca and Janssen-Cilag and a travel grant from Janssen-Cilag. LB received honoraria from Seattle Genetics, Sanofi, Astellas, Amgen, consultancy fee from Gilead, Hexal, and Menarini, consultancy fee and honoraria from Abbvie, BMS/Celgene, Daiichi Sankyo, Janssen, Jazz Pharmaceuticals, Novartis and Pfizer, and research funding from Bayer and Jazz Pharmaceuticals. CG-V received honoraria for lectures from Gilead Sciences, MSD, Novartis, Pfizer, Janssen, Lilly, GSK, Menarini and grants from Gilead Science, Pfizer and MSD. RH received a research grant from Gilead and honoraria for lectures from Pfizer and Gilead. JM received research grants from Gilead Sciences, MSD and Pfizer, is or has been a consultant to Amlyx, Astellas, Basilea, F2G Ltd, Cidara, Scynexis, Gilead Sciences, MSD and Pfizer, and served at the speakers' bureau of Astellas, Basilea, Gilead Sciences, MSD, Pfizer, Cidara and F2G Ltd. MP has received honoraria and grant for talks and projects on behalf of Pfizer. LP was board member of Gilead Sciences, MSD, Pfizer, Basilea, Janssen, Novartis, Jazz Pharmaceuticals, Cidara and has been speaker for Gilead Sciences, MSD, Pfizer Pharmaceuticals, Astellas Pharma, Novartis, Jazz Pharmaceutical and served as consultant for Menarini and Cidara. ATB received consultancy fees and honoraria from Gilead Sciences, Pfizer, MSD and Takeda. TC reported advisory board membership from Cytosorbent, ThermoFisher, GE Healthcare and Gentian and data monitoring board membership from Cidara and Lymphatica (with fees paid to his institution). All indicated contacts are outside the submitted work. No financial support was provided for the submitted work.

## ADDITIONAL INFORMATION

**Correspondence** and requests for materials should be addressed to Georg Maschmeyer.

**Reprints and permission information** is available at <http://www.nature.com/reprints>

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2022